KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Total Current Liabilities (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Total Current Liabilities for 7 consecutive years, with $68.4 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Total Current Liabilities fell 3.72% year-over-year to $68.4 million, compared with a TTM value of $68.4 million through Mar 2025, down 3.72%, and an annual FY2024 reading of $97.8 million, up 26.66% over the prior year.
  • Total Current Liabilities was $68.4 million for Q1 2025 at Aurinia Pharmaceuticals, down from $97.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $97.8 million in Q4 2024 and bottomed at $21.2 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $56.4 million, with a median of $53.9 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities soared 78.08% in 2023, then fell 3.72% in 2025.
  • Year by year, Total Current Liabilities stood at $40.6 million in 2021, then increased by 13.44% to $46.1 million in 2022, then skyrocketed by 67.41% to $77.2 million in 2023, then rose by 26.66% to $97.8 million in 2024, then crashed by 30.03% to $68.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for AUPH at $68.4 million in Q1 2025, $97.8 million in Q4 2024, and $78.6 million in Q3 2024.